Agios Pharmaceuticals (AGIO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Agios Pharmaceuticals

NasdaqGS•Healthcare•Biotechnology

$33.89+0.94(0.03%)Market open

Market Cap

$2.00B

P/S

20.3x

P/B

1.9x

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

How this company scores

AverageMetricSide Score: 43/100

Strongest: Growth (15/25); weakest: Profitability (5/25).

Profitability5/25

Growth15/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Growing revenueInterest easily coveredConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 3.0x5y range 1.3x – 3.8x

Currently near its 6-quarter median.

P/S · 20.3x5y range 20.3x – 1925.2x

Currently below its 19-quarter median.

P/B · 1.9x5y range 1.1x – 3.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.00B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $98.34M
Q. Revenue: $44.74M
TTM EBITDA: $-459.02M
TTM Op. Income: $-459.02M
Q. Op. Income: $-110.55M
TTM Net Income: $-411.29M
Q. Net Income: $-100.70M
EPS: $-1.69
Shares Out.: $59.49M

$98.34M in TTM revenue grew 140.6% YoY, reaching $44.74M last quarter. TTM EBITDA of $-459.02M and TTM operating income of $-459.02M show growth is flowing through to the bottom line. However, net income is negative at $411.29M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 93.3%
EBITDA Margin: -247.1%
Op. Margin: -247.1%
Net Margin: -225.1%

Op. margin of -247.1% is up 773.0% YoY — cost efficiency is improving. Net margin at -225.1% and gross margin of 93.3% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 5 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 20.3x
P/B Ratio: 1.9x

P/S of 20.3x and P/B of 1.9x. P/S is high, meaning growth expectations are priced in. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.11B
Cash: $99.65M
Long-Term Debt: N/A
Book Value: $1.03B
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-57.31M
TTM Free Cash Flow: $-365.25M
FCF Margin: -371.4%
FCF / Net Income: 0.9

TTM FCF of $-365.25M on $-57.31M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 11% — an improving trend.